Literature DB >> 29032510

Current prognostic and predictive factors in follicular lymphoma.

Marc Sorigue1, Juan-Manuel Sancho2.   

Abstract

Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day treatments, long remissions are often achieved both in the front-line and relapsed setting. However, a subset of patients has a more aggressive course and a worse outcome. Their identification is the main purpose of modern day prognostic tools. In this review, we attempt to summarize the evidence concerning prognostic and predictive factors in FL, including (1) pre-treatment factors, from baseline clinical characteristics and imaging tests to histological grade, the microenvironment and genomic abnormalities; (2) post-treatment factors, i.e., depth of response, measured both by imaging tests and minimal residual disease; (3) factors at relapse and duration of response; and (4) prognostic factors in histological transformation. We conclude that, despite the existence of numerous tools, the availability of some of them is still limited; they generally suffer from notable downsides, and most have unproven predictive value, thus having scarce bearing on the choice of regimen at present. However, with the technological and scientific developments of the last few years, the potential for these prognostic factors is promising, particularly in combination, which will probably, in time, help guide therapeutic decisions.

Entities:  

Keywords:  Follicular lymphoma; Genetic mutations; Microenvironment; Minimal residual disease; Pet; Prognostic factors; Refractoriness to therapy

Mesh:

Substances:

Year:  2017        PMID: 29032510     DOI: 10.1007/s00277-017-3154-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Authors:  Xiaoyu Qu; Hongli Li; Rita M Braziel; Verena Passerini; Lisa M Rimsza; Eric D Hsi; John P Leonard; Sonali M Smith; Robert Kridel; Oliver Press; Oliver Weigert; Michael LeBlanc; Jonathan W Friedberg; Min Fang
Journal:  Blood       Date:  2018-11-16       Impact factor: 22.113

2.  Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.

Authors:  Frédérique St-Pierre; Stephen M Broski; Betsy R LaPlant; Matthew J Maurer; Kay Ristow; Gita Thanarajasingam; William R Macon; Thomas M Habermann; Thomas E Witzig
Journal:  Oncologist       Date:  2020-04-28

Review 3.  Novel Therapy Approaches to Follicular Lymphoma.

Authors:  Michael Northend; William Townsend
Journal:  Drugs       Date:  2021-03       Impact factor: 9.546

Review 4.  Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

Authors:  Timothy M Pierpont; Candice B Limper; Kristy L Richards
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

Review 5.  Dural Follicular Lymphoma: Case Report and Literature Review.

Authors:  Ellery Altshuler; Raymond Richhart; Umar Iqbal; Joanna Chaffin
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

Review 6.  Abnormal microRNA expression in the course of hematological malignancies.

Authors:  Agnieszka Szymczyk; Arkadiusz Macheta; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2018-10-08       Impact factor: 3.989

7.  Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma.

Authors:  Mixue Xie; Lulu Wang; Qi Jiang; Xuxia Luo; Xin Zhao; Xueying Li; Jie Jin; Xiujin Ye; Kui Zhao
Journal:  Cancer Cell Int       Date:  2021-07-26       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.